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Abstract 
Background 
Comparing the relationships of antihypertensive medications with brachial blood pressure 
(BP) and aortic waveform parameters may help clinicians to predict the effect on the latter in 
brachial BP-based antihypertensive therapy. We aimed to make such comparisons with new 
waveform measures and a wider range of antihypertensive regimens than examined 
previously. 
Methods 
Cross-sectional analysis of 2933 adults (61% male; aged 50–84 years): 1637 on 
antihypertensive treatment and 1296 untreated hypertensives. Sixteen medicine regimens of 
up to 4 combinations of drugs from 6 antihypertensive classes were analysed. Aortic systolic 
BP, augmentation index (AIx), excess pressure integral (EPI), backward pressure amplitude 
(Pb), reflection index (RI) and pulse wave velocity (PWV) were calculated from aortic 
pressure waveforms derived from suprasystolic brachial measurement. 
Results 
Forest plots of single-drug class comparisons across regimens with the same number of drugs 
(for between 1- and 3-drug regimens) revealed that AIx, Pb, RI and/or loge(EPI) were higher 
(maximum difference = 5.6%, 2.2 mm Hg, 0.0192 and 0.13 loge(mm Hg ⋅ s), respectively) 
with the use of a beta-blocker compared with vasodilators and diuretics, despite no brachial 
systolic and diastolic BP differences. These differences were reduced (by 34–57%) or 
eliminated after adjustment for heart rate, and similar effects occurred when controlling for 
systolic ejection period or diastolic duration. 
Conclusions 
Beta-blocker effects on brachial BP may overestimate effects on aortic waveform parameters. 
Compared to other antihypertensives, beta-blockers have weaker associations with wave 
reflection measures and EPI; this is predominantly due to influences on heart rate. 
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Introduction 
Antihypertensive medications are widely utilised and prevent incident cardiovascular (CV) 
events. While brachial blood pressure (BP) is routinely used as a target in such therapy, new 
technological advances have made it possible to make practical, non-invasive measurements 
that provide estimates of aortic pressure waveforms [1]. Aortic waveform parameters, which 
include aortic systolic BP (SBP), augmentation index (AIx) and pulse wave velocity (PWV), 
have been shown to predict CV events independently of brachial BP [2, 3]. Thus, given their 
relationships with CV risk and their easy measurement in clinical practice, they may be 
useful targets in antihypertensive therapy. In support of this, large trials have found that 
antihypertensives have clinical benefits beyond those expected from decreases in brachial BP 
[4, 5]. 
However, there are some issues associated with antihypertensive therapy based on aortic 
waveform parameters that appear to warrant further research. One issue is the relative 
efficacies of various antihypertensive polytherapies on these parameters. A few studies have 
compared the effectiveness on these waveform measures of two drugs used in combination 
[6, 7, 8, 9, 10] but we are not aware of any published study that has compared combinations 
of three or more antihypertensives. Further, these studies measured a limited range of 
parameters and drug combinations. In addition, some believe that heart rate and the diastolic 
filling period may account for differences between antihypertensive classes [11, 12] and that 
ejection duration may also play a role [13], although the sizes of these contributions are 
largely unknown. 
A second issue is the degree to which changes in brachial BP following antihypertensive 
therapy reflect changes in aortic waveform parameters. In other words, how well does 
brachial BP measurement capture effects of antihypertensives on these parameters? 
Knowledge of this would help clinicians to predict the effect on the latter when brachial BP is 
used as a target in such therapy. One body of evidence that informs such predictions is a 
meta-analysis of clinical trials, which showed that, relative to their effects on brachial BP, 
antihypertensives had differential effects on central BP and AIx [14]. Other clinical trials 
have shown that different antihypertensives had similar effects on brachial BP yet differential 
effects on other waveform parameters [10, 15]. However, as this prior research measured a 
limited scope of parameters and drug combinations, study of a wider range of waveform 
parameters and antihypertensive regimens appears worthwhile. 
The objectives of this paper were to: 1) compare associations that various antihypertensives 
(no treatment, monotherapies and polytherapies) have with BP variables (waveform 
parameters) and, 2) examine the contributions of heart rate, systolic ejection period (SEP) and 
diastolic duration to therapy-related differences in these associations. Particular attention was 
given to beta-blockers (βBs) as previous studies have found them to be less effective than 
other antihypertensives in reducing some of these parameters [7, 16, 17, 18]. To build on 
existing research, in our analyses, we included a wider range of aortic waveform measures 
and antihypertensive regimens than used in previous studies. 
 
Material and methods 
 
Participants 
The present study is a baseline (cross-sectional) analysis of the ViDA (Vitamin D 
Assessment) study, a randomised controlled trial of the health effects of vitamin D 
supplementation. Inclusion criteria were men and women aged 50–84 years and resident in 
Auckland at recruitment. Exclusion criteria included: 1) diagnosis of a terminal illness and/or 
in hospice care, 2) intending to leave New Zealand during the follow-up period, 3) taking 
vitamin D supplements (including cod liver oil) of > 600 IU per day, 4) history of renal 
stones, hypercalcaemia, or medical conditions that can cause hypercalcaemia and 5) baseline 
serum calcium > 2.50 mmol/L. All baseline data were collected during 2011–2012. Ethics 
approval was provided by the Ministry of Health Multi-region Ethics Committee. Written, 
informed consent was obtained from each participant. Full details have been published 
elsewhere [19]. 
 
Anthropometry, demographics and past medical history 
All measurements were carried out by trained staff using a standardised protocol. Without 
shoes and in light clothing, height was measured with a stadiometer (± 0.1 cm) and weight 
with digital scales (± 0.1 kg). Body mass index (BMI) was calculated as weight (kg)/height 
(m)2. 
Demographic and past medical history data were collected via questionnaires administered by 
trained interviewers. Ethnicity was defined by self-identification. Because patients may be 
more likely to be administered specific antihypertensives if they have diabetes or heart failure 
[20], and this could introduce indication bias in our analyses, we recorded these conditions at 
baseline. Participants were identified as having diabetes if they indicated that they had been 
told by a doctor that they have diabetes and were currently receiving insulin, medicines, 
tablets or pills as treatment. Participants were identified as having a history of heart failure if 
they had been told by a doctor that they have heart failure. 
 
Medications 
Records of all medicine prescriptions dispensed for participants before and after their 
interview dates were collected from the Ministry of Health. Such data included the medicine 
name, dose, daily dose, frequency and days of supply. To determine that measured waveform 
parameters could be influenced by prescribed medicines, these medicines must have been 
taken just prior to the interview. Therefore, medication use was defined as the prescription of 
a medication with days of supply that encompassed the interview date. Medicines were 
categorised into nitrates and six major antihypertensive classes: alpha blockers, angiotensin-
converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), βBs, calcium 
channel blockers (CCBs) and diuretics. βBs were divided into vasodilating and non-
vasodilating βBs, while diuretics were separated into thiazide(-like), loop and potassium-
sparing diuretics, as these therapeutic sub-classes may have differential relationships with BP 
variables [21, 22]. 
 
BP variables 
After 15 minutes rest while sitting, BP (± 1 mm Hg) was measured three times with an 
Omron T9P oscillometric device (Omron Healthcare, Kyoto, Japan) placed above the cubital 
fossa of the left arm and the mean of the two closest measurements were used for analyses. 
Suprasystolic oscillometry was carried out using a BP + device (Uscom, Sydney, Australia) 
(formerly called a R6.5 cardiovascular monitor; Pulsecor, Auckland, New Zealand), with an 
appropriately sized cuff positioned on the left upper arm. The BP + device has been shown 
to: 1) yield central systolic blood pressures that are highly correlated with those assessed by 
catheter measurement at the ascending aorta or aortic arch [23] and, 2) measure central 
systolic BP with good intratest and intertest reliability [24]. To improve the quality of the 
waveforms used in analyses, we decided a priori to exclude readings with a signal-to-noise 
ratio of < 6 dB. 
Augmentation index (AIx), an index of arterial stiffness and wave reflection [25], was 
calculated from the aortic pressure waveform using custom-written Matlab software 
(Mathworks, Natick, MA). A meta-analysis has shown AIx to be a predictor of CV events 
[2]. 
Aortic pressure was separated into reservoir and wave components using custom-written 
Matlab software (Mathworks, Natick, MA). Reservoir pressure was calculated from pressure 
measurements, as described elsewhere [26]. Excess pressure was calculated as measured 
pressure minus reservoir pressure [27]. The integral of the excess pressure waveforms (area 
under these waveforms) over the cardiac cycle was used to calculate excess pressure integral 
(EPI). EPI measures pressure associated with excess ventricular work and has been shown to 
predict CV events independently of brachial SBP [26]. 
Wave separation analysis was used to separate the aortic pressure waveform into forward and 
backward components [28]. The amplitude of backward pressure (Pb) was then calculated. Pb 
determined from this technique has previously been shown to be similar to values obtained 
using aortic flow waveforms measured by Doppler ultrasound [29]. Moreover, Pb has been 
shown to predict mortality [30] and CV events [31] independently of brachial BP. Reflection 
index (RI) was defined as Pb divided by the sum of Pb and the amplitude of the forward 
pressure [15, 31]. 
PWV was calculated from the aortic pressure waveform using validated algorithms and 
derived PWV values have been shown to predict CV events independently of brachial BP 
[32, 33]. PWV is a known predictor of CV events, as demonstrated in a meta-analysis [3]. 
The periods of time from the incisura to the start and end of the aortic waveform were taken 
as the SEP and diastolic duration, respectively [10]. 
 
Statistical analysis 
Data were analysed using SAS version 9.3 (SAS Institute, Cary, NC). Statistical significance 
was set at P < 0.05. Because of the positively skewed distribution of EPI, this was converted 
to loge for analyses. Among untreated participants, hypertensives were defined as those with 
a brachial SBP of ≥ 140 mm Hg and/or a brachial diastolic BP (DBP) of ≥ 90 mm Hg. 
Characteristics of participants across therapies (none and treatment regimens) were compared 
using ANOVA (for continuous variables) and χ2 tests (for categorical variables). 
Associations between medicines and BP variables were examined by multivariate linear 
regression, with potential confounders, age, sex and ethnicity, included as covariates. Further 
adjustment for BMI, height, diabetes mellitus, heart failure and nitrate use had minimal 
influence on the regression coefficients of the antihypertensive regimen variables, and results 
for these less parsimonious statistical models are not reported. For comparisons between 
untreated and treated people, the former was restricted to those who were hypertensive and 
was coded as the reference group. This is because at the onset of antihypertensive therapy, 
treated participants are assumed to have been hypertensive as this is an implicit requirement 
of such therapy. Accordingly, untreated normotensives were excluded from all analyses. 
Including this exclusion group would introduce unwanted reverse causation (higher brachial 
BP encouraging clinicians to prescribe antihypertensives) as these participants would have 
brachial BP that is too low to warrant treatment. Heart rate, SEP and diastolic duration were 
separately added to these models to explore their effects on the relationships. 
Differences in BP variables across antihypertensive regimens among treated participants only 
were examined for statistical significance with the F test. This was done separately for 1- and 
all-drug regimens. In each case, the reference group was the regimen with the highest sample 
size. 
Using Review Manager version 5.2 (Nordic Cochrane Centre, Copenhagen) [34], forest plots 
were constructed to illustrate the associations between differences in antihypertensive 
regimens and BP variables. These show the effect sizes and associated 95% confidence 
intervals for each pairwise regimen comparison. Overall estimates of the pooled relation were 
calculated using inverse-variance weighting and with the use of random-effects models (to 
account for differences in drugs and daily doses across comparisons in each forest plot). 
Bivariate correlations between BP variables, pulse rate, SEP and diastolic duration were 
summarised with Pearson correlation coefficients (r). 
 
Results 
Table 1 shows participant characteristics and details of their antihypertensive therapy. Sixteen 
different medicine regimens were analysed: six 1- (n = 840), six 2- (n = 494), three 3- 
(n = 240) and one 4- (n = 63) drug combinations of antihypertensives grouped into their 
classes. Across these regimens, age, sex (both P < 0.0001) and ethnicity (P = 0.0029) varied. 
Supplementary Table S1 shows the daily doses of the antihypertensives used in these 
regimens. There was a broad range of drugs and daily doses. While the composition of the 
regimens was heterogeneous, some antihypertensives made up a significant proportion of 
their respective class: bendrofluazide and hydrochlorothiazide (diuretics), cilazapril (ACE 
inhibitors), metoprolol (βBs) and felodipine (CCBs). 
 
Waveform parameters differences between untreated and treated people 
Differences in waveform parameters between untreated and treated participants are shown in 
Table 2. For all regimens, brachial SBP and DBP were lower with antihypertensive use 
compared to untreated. The difference between treated and untreated ranged from ~ 9 to 
18 mm Hg for brachial SBP and from ~ 3 to 9 mm Hg for brachial DBP. Across all regimens, 
brachial SBP did not vary (P = 0.17) but AIx, loge(EPI), Pb and RI (all P ≤ 0.0001) did. 
Similarly, across the 1-drug regimens, there was no difference in brachial SBP (P = 0.23) and 
DBP (P = 0.21) but there were differences in AIx (P = 0.0002), Pb (P = 0.023) and RI 
(P < 0.0001). AIx, loge(EPI), Pb and RI were consistently higher in regimens containing βBs 
(shaded rows) compared to regimens without βBs. This was both true for monotherapies and 
combination therapies. Therefore, whether alone or combined with other drugs, the presence 
of βBs appear to be a potential reason for differences in wave reflection measures and 
loge(EPI) between the regimens. 
 
Pairwise comparisons between beta-blockers and other antihypertensives 
Given the differences between βBs and non-βBs, forest plots were constructed, which more 
closely compare differences in BP variables between those on these two regimen groups 
(Supplementary Fig. S1). Each forest plot compares βBs (the reference group) with one other 
antihypertensive class. Drugs from other antihypertensive classes are controlled for as they 
are either absent (in the case of monotherapy comparisons, such as βB-versus-CCB) or are 
present in both of the regimens being compared (in the case of polytherapy comparisons, 
such as ACEI/βB-versus-ACEI/CCB comparisons and D/ACEI/βB-versus-D/ACEI/CCB 
comparisons, which both compare βBs with CCBs, controlling for other antihypertensive 
classes). Compared to participants on βBs, those on CCBs did not differ in brachial SBP 
(P = 0.69) and DBP (P = 0.63) but had lower AIx (pooled effect = 3.90, P < 0.0001), 
loge(EPI) (pooled effect = 0.10 loge(mm Hg ⋅ s), P = 0.001), Pb (pooled effect = 2.16 mm Hg, 
P < 0.0001) and RI (pooled effect = 0.019, P < 0.0001). Similarly, compared to participants 
on βBs, those on ACEIs did not differ in brachial SBP (P = 0.58) and DBP (P = 0.80) but had 
lower AIx (pooled effect = 4.16, P < 0.0001), loge(EPI) (pooled effect = 0.12 
loge(mm Hg ⋅ s), P = 0.002), Pb (pooled effect = 1.71 mm Hg, P = 0.001) and RI (pooled 
effect = 0.014, P < 0.0001). Compared to participants on βBs, those on diuretics did not differ 
in brachial SBP (P = 0.23) and DBP (P = 0.93) but had lower loge(EPI) (pooled effect = 0.09 
loge(mm Hg ⋅ s), P = 0.01) and RI (pooled effect = 0.0138, P = 0.010). In a similar manner, 
compared to participants on βBs, those on ARBs did not differ in brachial SBP (P = 0.10) and 
DBP (P = 0.05) but had lower AIx (pooled effect = 5.59, P < 0.0001), loge(EPI) (pooled 
effect = 0.13 loge(mm Hg ⋅ s), P = 0.004) and RI (pooled effect = 0.017, P < 0.0001). 
The samples of individual regimens in each forest plot were then combined – an aggregated 
sample for those based on βBs (which appear second in the pair of regimens listed in each 
forest plot) and a separate aggregated sample for those based on the antihypertensive class 
they were compared to (which appear first in the pair of regimens listed in each forest plot). 
Differences in BP variables between these combined samples are shown in Table 3. These 
values are analogous (similar) to the pooled estimates in the forest plots as both comparisons 
are based on the same samples. This table shows that, compared to participants on βBs, those 
on other antihypertensives did not differ in brachial SBP and DBP but had lower loge(EPI), 
AIx, Pb and/or RI. These results are similar to those from the forest plots, despite the fact that 
the βB-other antihypertensive comparisons are calculated differently. 
 
Contribution of heart rate, SEP and diastolic duration to waveform parameter 
differences 
To understand the contribution of heart rate to differences in parameter levels across βB and 
non-βB regimens, heart rate differences were firstly determined. These differences are shown 
in Table 3, which indicates that βBs were associated with slower heart rates than ACEIs, 
CCBs, diuretics and ARBs. Secondly, correlations between heart rate and waveform 
parameters were examined and these revealed negative relationships (r = − 0.04 to − 0.39). 
This suggests that a slower heart rate associated with βBs could contribute to higher levels of 
waveform parameters, which was confirmed by adjusting the initial models shown in Table 3 
for heart rate. Thus, correction for heart rate reduced (by 34–57%) or in some cases 
eliminated differences between βB and non-βB regimens (Table 3). 
Similar analyses were applied to explore the effect of the length of systole and diastole. SEP 
and diastolic duration were longer among those on βB regimens (Table 3). Further, SEP was 
positively associated with all parameters (r = 0.12 to 0.53) except brachial DBP (r = − 0.04); 
while diastolic duration was positively correlated with all parameters (r = 0.05 to 0.35) except 
brachial SBP (P = 0.91) and DBP (r = − 0.17). This implied that SEP and diastolic duration 
should contribute to the differences between βB and other antihypertensives, which was 
verified by adjusting the initial models shown in Table 3 for these variables. Thus, controlling 
for the length of systole or diastole attenuated or removed differences in parameter levels 
across βB and non-βB regimens (Table 3). 
 
  
Effect of vasodilating beta-blockers and non-thiazide(− like) diuretics 
Vasodilating beta-blockers and non-thiazide(-like) diuretics (sample sizes shown in 
Supplementary Table S1) were subsequently excluded from the analyses for Table 
2 and Table 3 and the modified results are shown in Supplementary Tables S2–S4. Removal 
of vasodilating βBs slightly reduced differences with untreated (Table S2) and slightly 
increased differences with non-βBs (Table S3). Exclusion of loop and/or potassium-sparing 
diuretics had minor effects on differences with untreated (Table S2) and βBs (Table S4). 
 
Discussion 
Compared to other antihypertensives, βBs were associated with similar levels of brachial SBP 
and DBP. Despite this, they were associated with higher AIx, loge(EPI), Pb and RI, 
suggesting that they have weaker relationships with these parameters. Variation in heart rate 
between βB and non-βB regimens contributed to these parameter differences. 
Compared with untreated hypertensive participants, people receiving antihypertensives had 
lower brachial SBP, brachial DBP, aortic SBP, AIx and PWV, which is in agreement with 
findings of clinical trials [7, 9, 16, 17, 18, 35]. Our study builds on these studies by 
quantifying the magnitude of these effects in a real-world setting, over a wider range of 
antihypertensive regimens and by showing that several antihypertensive regimens also may 
reduce Pb and RI (Table 2). Another original finding is that, in several cases, EPI varied 
between untreated and treated participants (Table 2), suggesting that it could be modified 
with regimens. Clinical trials are required to confirm this. 
The weaker AIx associations with the use of βBs compared to other antihypertensives 
concurs with clinical trials [7, 16, 17, 18]. We extend this prior work by showing that this is 
also true for polytherapies including βBs, and by demonstrating that βBs additionally have 
weaker associations with other waveform parameters – EPI, Pb and RI – particularly when 
compared with ACEIs and CCBs. Some meta-analyses and large clinical trials have shown 
βBs to be inferior to other antihypertensives in preventing CV events [36]. This may be 
explained by these weaker associations with waveform parameters. Altogether, this supports 
the view that βBs are not optimal drug choices in antihypertensive monotherapy and 
polytherapy. 
Little is known about how much of antihypertensive effects on waveform parameters are 
mediated through effects on heart rate and SEP. Clinical trials have reported antihypertensive 
effects on heart rate and/or SEP but did not quantify the contribution of these to effects on BP 
variables [8, 10, 16, 17, 37, 38, 39]. An exception to this is the finding from the CAFE study 
that differential effects of amlodipine- and atenolol-based regimens on aortic BP were 
predominantly mediated by influences on heart rate [11]. We build on this prior research in 
two ways. First, by showing that heart rate and SEP largely account for differential 
relationships with AIx, Pb and RI. Second, by demonstrating that this not only applies to 
comparisons between a βB and CCB (which was the focus of the CAFE study [11]), but 
additionally to differences that βBs have with diuretics, ACEIs and ARBs (Table 3). But 
heart rate is not the only factor accounting for variation between βBs and non-βBs as some 
differences remained after it was adjusted for (Table 3). Vasodilators (such as CCBs) may 
reduce the magnitude of the reflected wave by attenuating the vascular tone of peripheral 
muscular arteries and improving impedance matching [9, 15]. Our results are consistent with 
this as we observed differences in RI between βBs and vasodilators (CCBs, ACIs and ARBs) 
after adjustment for heart rate (Table 3). 
It has been proposed that a slower heart rate increases the filling time of the ventricles, 
increasing preload, stroke volume and consequently aortic pulse pressure [12]. Whether this 
accounts for effects of antihypertensives on aortic waveform parameters has not been 
previously explored. Therefore, as recommended [40], we investigated whether influences on 
the diastolic filling period account for associations between antihypertensives and these 
parameters. Our results support this possibility (Table 3). 
Given that βBs were associated with higher levels of aortic waveform parameters yet similar 
levels of brachial BP variables than non-βBs, effects on the former may be overestimated by 
brachial BP responses to βB therapy. This is important since brachial SBP and DBP are 
routinely used as targets in antihypertensive therapy, yet aortic waveform parameters may be 
more strongly or independently related to CV events [26, 31]. Clinical trials have found that, 
compared to their impact on brachial SBP, βBs have less favourable effects on AIx [14]. Our 
findings build on from this prior research by showing that, in addition to AIx, this may be 
true for EPI, Pb, RI and aortic PWV. Thus, our results support implementing the 
measurement of central waveform parameters to monitor their responses to antihypertensive 
therapy rather than reliance on brachial BP alone. 
The use of two antihypertensives is often inadequate to control BP but there is little data 
assessing the efficacy of specific combinations of three or more drugs on brachial and central 
BP [41]. Our finding that a ACEI/CCB combination was associated with the most favourable 
(lowest) aortic waveform parameter profile out of all dual therapies is in accordance with 
clinical trials which have suggested that this is one of the preferred combination therapies for 
reducing brachial BP and preventing cardiovascular morbidity [42]. Out of all polytherapies 
of at least three medicines, the ACEI/CCB/D combination had the lowest levels of aortic 
waveform parameters. This supports the use of this regimen in polytherapy to achieve 
optimal benefits on waveform parameters. Clinical trials are required to verify whether this 
approach is also optimal in terms of CV events. 
Diuretics and beta-blockers predominantly comprised the thiazide(-like) diuretic and non-
vasodilating beta-blocker subgroups (Supplementary Tables S1–S4), respectively, so their 
results are mostly applicable to these subgroups. The small reductions in differences in 
parameter levels compared to untreated (Table S2) and small increases in the differences 
compared to non-βBs (Table S3) when vasodilating βBs were excluded from analyses are 
consistent with the view that these drugs are associated with greater decrements in parameter 
levels than non-vasodilating βBs. A few intervention studies (which measured brachial and 
central SBP) support this [21] but additional trials are required to confirm whether this is true 
for the new parameters we measured (such as Pb and RI). 
The observational nature of this analysis means that the findings are prone to confounding 
and cannot establish causal links. However, as demonstrated above, our results are consistent 
with those from clinical trials. For example, brachial SBP was 9–18 mm Hg lower in treated 
participants than in untreated people, which concurs with effect sizes reported in clinical 
trials [43]. In addition, we adjusted for indication bias by controlling for diabetes and heart 
failure. While residual confounding cannot be excluded, confounding from reverse causation 
does not seem to be a major explanation for the findings for the following reasons. First, as 
previously explained (Section 2.5), the inclusion of untreated normotensives introduces 
reverse causation, but this was reduced by excluding these participants from analyses. 
Second, reverse causation would create positive antihypertensive-brachial BP relationships 
since clinicians would prescribe antihypertensives to counter increases in brachial BP, but we 
did not observe such associations. Third, comparisons were made within regimens with the 
same number of drugs but reverse causation would more likely arise when comparing 
regimens with different numbers of drugs since additional drugs would be administered to 
counter difficulties in reducing brachial SBP and/or DBP. Therefore, forward causation 
(medicines influencing BP variables) appears to have dominated instead. Strengths of this 
study are the large sample size, the wide range of waveform parameters and the ability to 
investigate the potential benefit of polytherapy. 
In summary, compared to other antihypertensives, βBs had the same associations with 
brachial BP variables but weaker associations with wave reflection measures and EPI, even 
when used in polytherapy. Thus, using brachial SBP and DBP as targets for antihypertensive 
therapy may, in the case of βBs, overestimate effects on central haemodynamic measures 
(such as AIx) which are independently related to risk of CV events [2, 3, 26, 31]. This 
supports the measurement of central waveform parameters to assess their responsiveness to 
antihypertensive therapy rather than reliance on brachial BP alone. 
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Table 1. Demographic characteristics of participants across monotherapies and polytherapies. 
 
Medicine regimen n Age (y)* 
Male 
(%) 
European/Other 
(%) 
Maori 
(%) 
Pacific 
(%) 
South 
Asian 
(%) 
Untreated hypertensives 1292 
66.3 
(0.2) 
57 83 4 8 4 
 
1 drug 
ACEI 355 
66.4 
(0.4) 
67 77 7 10 6 
αB 51 
70.3 
(1.1) 
98 96 2 2 0 
ARB 77 
68.2 
(0.9) 
61 90 3 3 5 
βB 134 
69.2 
(0.7) 
64 84 7 0 10 
CCB 125 
70.1 
(0.7) 
60 86 8 2 5 
D 86 
69.3 
(0.9) 
36 91 3 6 0 
 
2 drugs 
ACEI + βB 73 
69.7 
(0.9) 
81 84 4 8 4 
ACEI + CCB 81 
70.5 
(0.9) 
67 73 9 14 50 
ACEI + D 199 
67.4 
(0.6) 
54 84 5 9 3 
ARB + D 44 
70.2 
(1.2) 
36 93 2 5 0 
Medicine regimen n Age (y)* 
Male 
(%) 
European/Other 
(%) 
Maori 
(%) 
Pacific 
(%) 
South 
Asian 
(%) 
βB + D 54 
70.1 
(1.1) 
36 87 6 4 4 
CCB + D 34 
71.4 
(1.4) 
32 88 6 3 3 
 
3 drugs 
ACEI + βB + CCB 43 
69.2 
(1.2) 
81 81 7 9 2 
ACEI + βB + D 82 
68.6 
(0.9) 
56 76 9 10 6 
ACEI + CCB + D 108 
68.1 
(1.0) 
59 79 9 8 4 
 
4 drugs 
ACEI + βB + CCB + D 62 
69.6 
(1.0) 
69 77 10 11 2 
 
P-value†  < 0.0001 < 0.0001 0.0029 
 
ACE = ACE inhibitor; αB = Alpha blocker; ARB = Angiotensin receptor blocker; βB = Beta-
blocker; CCB = Calcium channel blocker; D = Diuretic. *Values are mean (standard error); †P-
values test for differences across all-drug regimens (those < 0.05 are in bold). 
  
Table 2. Variation in blood pressure variables across monotherapies and polytherapies1. 
 
1Values are means (standard error) for untreated hypertensives (reference group) and differences in means (standard error) for all other values 
(adjusted for age, sex and ethnicity). ACE = ACE inhibitor; αB = Alpha blocker; ARB = Angiotensin receptor blocker; βB = Beta-blocker; 
CCB = Calcium channel blocker; D = Diuretic. *P < 0.05, †P < 0.01 and ‡P < 0.001 compared to untreated hypertensives; #P-values test for 
differences within 1-, 2-, 3- and all-drug regimens (those < 0.05 are in bold). Results for βB regimens are shaded. 
Table 3. Differences in blood pressure (BP) variables between participants on beta-blockers and 
those on drugs from other antihypertensive classes. 
 
Comparison group 
Reference group (βB 
regimens) 
BP 
variable 
Difference (standard error)† 
 
Initial 
model 
(IM) 
IM + heart 
rate 
IM + SEP IM + DD 
CCB regimens 
CCB or 
(CCB + ACEI) or 
(CCB + D) or 
(CCB + D + ACEI) 
βB or (βB + ACEI) or 
(βB + D) or 
(βB + D + ACEI) 
bSBP 
− 0.1 
(1.4) 
0.7 (1.5) 1.5 (1.4) 0.6 (1.5) 
bDBP 
− 0.3 
(0.8) 
− 1.4 (0.8) − 0.4 (0.8) 
− 1.4 
(0.8) 
aSBP 
− 1.9 
(1.4) 
− 0.3 (1.4) 0.2 (1.4) 
− 0.7 
(1.4) 
AIx 
− 4.1 
(0.9)* 
− 0.7 (0.8) 
− 1.8 
(0.8)* 
− 1.0 
(0.8) 
loge(EPI) 
− 0.10 
(0.03)* 
0.01 (0.03) 
− 0.02 
(0.03) 
− 0.01 
(0.03) 
Pb 
− 2.1 
(0.5)* 
− 0.5 (0.5) − 0.8 (0.5) 
− 0.6 
(0.5) 
RI 
− 19.3 
(2.6)* 
− 12.5 
(2.6)* 
− 12.7 
(2.4)* 
− 13.3 
(2.6)* 
PWV 
0.0 
(0.1) 
0.1 (0.1) 0.1 (0.1) 0.0 (0.1) 
HR 
6.8 
(0.8)* 
. . . 
SEP 
− 12.7 
(2.1)* 
. . . 
DD 
− 90.0 
(11.6)* 
. . . 
ACEI regimens 
ACEI or (ACEI + D) 
βB or (βB + D) 
bSBP 
− 0.9 
(1.5) 
− 0.3 (1.6) 1.2 (1.5) 
− 0.7 
(1.6) 
bDBP 
0.1 
(0.9) 
− 0.4 (0.9) 0.3 (0.9) 
− 0.6 
(0.9) 
aSBP 
− 1.8 
(1.5) 
− 0.6 (1.5) 1.0 (1.5) 
− 1.1 
(1.5) 
AIx 
− 4.3 
(0.9)* 
− 1.9 (0.9)* − 1.3 (0.8) 
− 2.0 
(0.9)* 
loge(EPI) 
− 0.12 
(0.03)* 
− 0.05 
(0.03) 
− 0.02 
(0.03) 
− 0.05 
(0.03) 
Pb 
− 1.7 
(0.5)* 
− 0.65 
(0.50) 
− 0.2 (0.5) 
− 0.8 
(0.5) 
RI 
− 14.0 
(2.8)* 
− 8.9 (2.7)* − 4.7 (2.5) 
− 9.5 
(2.8)* 
PWV 
− 0.0 
(0.1) 
0.0 (0.1) 0.1 (0.1) 0.0 (0.1) 
HR 
5.1 
(0.9)* 
. . . 
SEP 
− 13.9 
(2.2)* 
. . . 
Comparison group 
Reference group (βB 
regimens) 
BP 
variable 
Difference (standard error)† 
 
Initial 
model 
(IM) 
IM + heart 
rate 
IM + SEP IM + DD 
DD 
− 73.3 
(12.0)* 
. . . 
D regimens 
D or (D + ACEI) or 
(D + CCB + ACEI) 
βB or (βB + ACEI) or 
(βB + CCB + ACEI) 
bSBP 
1.0 
(1.5) 
1.2 (1.6) 2.8 (1.6) 0.8 (1.6) 
bDBP 
1.0 
(0.8) 
0.2 (0.9) 1.0 (0.9) 0.0 (0.8) 
aSBP 
− 0.2 
(1.5) 
0.8 (1.6) 2.2 (1.5) 0.2 (1.5) 
AIx 
− 4.5 
(1.0)* 
− 1.6 (0.9) − 1.5 (0.9) 
− 2.0 
(0.9)* 
loge(EPI) 
− 0.09 
(0.03)* 
− 0.01 
(0.03) 
− 0.00 
(0.03) 
− 0.02 
(0.03) 
Pb 
− 1.5 
(0.5)* 
− 0.4 (0.5) − 0.1 (0.5) 
− 0.6 
(0.5) 
RI 
− 14.4 
(2.6)* 
− 9.0 (2.6)* 
− 7.1 
(2.4)* 
− 10.4 
(2.6)* 
PWV 
0.1 
(0.1) 
0.1 (0.1) 0.2 (0.1)* 0.1 (0.1) 
HR 
5.6 
(0.9)* 
. . . 
SEP 
− 13.7 
(2.2)* 
. . . 
DD 
− 72.3 
(12.2)* 
. . . 
ARB regimens 
ARB or (ARB + D) 
βB or (βB + D) 
bSBP 
3.4 
(2.1) 
4.3 (2.3) 5.6 (2.2)* 3.9 (2.3) 
bDBP 
2.3 
(1.2) 
0.1 (1.3) 1.5 (1.3) 0.4 (1.3) 
aSBP 
2.0 
(2.0) 
3.6 (2.2) 5.0 (2.1)* 3.0 (2.2) 
AIx 
− 5.8 
(1.3)* 
− 2.0 (1.3) − 2.0 (1.3) 
− 2.5 
(1.3) 
loge(EPI) 
− 0.13 
(0.05)* 
0.02 (0.05) 
0.01 
(0.04) 
− 0.01 
(0.05) 
Pb 
− 1.3 
(0.8) 
1.1 (0.8) 1.1 (0.7) 0.6 (0.8) 
RI 
− 16.5 
(3.8)* 
− 8.2 (4.0)* − 3.3 (3.6) 
− 9.8 
(4.0)* 
PWV 
0.2 
(0.1) 
0.3 (0.1)* 0.3 (0.1)* 0.2 (0.1)* 
HR 
9.0 
(1.2)* 
. . . 
SEP 
− 21.6 
(3.1)* 
. . . 
Comparison group 
Reference group (βB 
regimens) 
BP 
variable 
Difference (standard error)† 
 
Initial 
model 
(IM) 
IM + heart 
rate 
IM + SEP IM + DD 
DD 
− 121.8 
(16.9)* 
. . . 
SEP = systolic ejection period (ms); DD = diastolic duration (ms); bSBP = brachial systolic BP 
(mm Hg); bDBP = brachial diastolic BP (mm Hg); aSBP = aortic systolic blood pressure (mm Hg); 
AIx = augmentation index; loge(EPI) = loge(excess pressure integral (mm Hg ⋅ s)); Pb = backward 
pressure (mm Hg); RI = Reflection index (× 10− 3); PWV = pulse wave velocity (m/s); HR = heart 
rate (beats/min); ACEI = ACE inhibitor; ARB = angiotensin receptor blocker; βB = beta-blocker; 
CCB = calcium channel blocker; D = diuretic. Initial model = BP variable regressed on 
antihypertensive comparison, age, sex and ethnicity. 
† Comparison group minus reference group. * P < 0.05. 
 
 
